Revance Therapeutics reported $293.88M in Current Assets for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Current Assets Change
Adamas Pharmaceuticals ADMS:US 108M 7.65M
Aerie Pharmaceuticals AERI:US $ 275.95M 13.07M
ALKERMES ALKS:US 1.05B 15.25M
Biodelivery Sciences International BDSI:US $ 188.26M 7.8M
Bristol Myers Squibb BMY:US $ 31443M 2282M
Cara Therapeutics CARA:US $ 171.5M 7.03M
Coherus Biosciences CHRS:US $ 673.04M 13.03M
Eli Lilly And LLY:US $ 17808.3M 512.8M
Endo International Ordinary Shares ENDP:US $ 2748.95M 179.62M
Flexion Therapeutics FLXN:US $ 192.76M 8.64M
Gw Pharmaceuticals GWPH:US $ 718.73M 10.8M
Horizon Pharma HZNP:US $ 2413.92M 238.54M
JAZZ PHA JAZZ:US $ 2628.23M 325.74M
Neurocrine Biosciences NBIX:US $ 1005.7M 104.4M
Pacira Pharmaceuticals PCRX:US $ 822.35M 29.77M
Procter & Gamble PG:US $ 24336M 1245M
Revance Therapeutics RVNC:US $ 293.88M 60.72M
Supernus Pharmaceuticals SUPN:US $ 668.38M 29.13M
Teva Pharmaceutical Industries TEVA:US $ 12154M 668M
Zogenix ZGNX:US $ 375.46M 40.93M